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SUMMARY
Six countries (Denmark, England and Wales, France, Germany, Italy and the Netherlands)
conducted large serological surveys for mumps, in the mid-1990s, as part of the European
Sero-Epidemiology Network (ESEN). The assay results were standardized and related to the
schedules and coverage of the immunization programmes and the reported incidence of mumps.
Low incidence of disease and few susceptibles amongst adolescents and young adults was
observed in countries with high mumps vaccine coverage (e.g. the Netherlands). High disease
incidence and large proportions of mumps virus antibody negative samples in adolescent and
young adult age groups was noted in countries with poor vaccine coverage (e.g. Italy). The
build-up of susceptibles in older children and adolescents in England and Wales, France,
the former West Germany and Italy indicate the possibility of further mumps outbreaks in
secondary school environments. To control mumps in western Europe, current MMR
immunization programmes will need to be strengthened in a number of countries.
Sero-surveillance of mumps is an important component of disease control and its usefulness
will be enhanced by the development of an international mumps standard.
INTRODUCTION
The classical symptoms of mumps are unilateral
or bilateral parotitis, although many cases exhibit
non-speciﬁc or primarily respiratory symptoms
[1, 2] and approximately a third of all infections are
asymptomatic [1, 3]. Infection is considered to pro-
vide lifelong immunity, although rare cases of re-
infection with mumps virus have been documented [4].
Mumps is often considered as a benign illness with a
low mortality, although the burden of disease should
not be underestimated [5]. Central nervous system
(CNS) complications are common, usually appearing
as aseptic meningitis, which occurs in approximately* Author for correspondence.
Epidemiol. Infect. (2003), 131, 691–701. f 2003 Cambridge University Press
DOI : 10.1017/S0950268803008768 Printed in the United Kingdom
5%of patients withmumps [1, 2]. In younger children,
mumps was the major cause of acquired sensorineural
deafness prior to the introduction of immunization
programmes [1]. Although orchitis is a common
complication after puberty, occurring in approxi-
mately a third of cases, sterility is rare [1].
A number of live attenuated mumps vaccines have
been developed and since the 1980s these vaccines
have been used increasingly as part of a trivalent
combination vaccine for measles, mumps and rubella
(MMR). The International Task Force for Disease
Eradication identiﬁed mumps as a potential target for
eradication, and recommended that this should be
linked to the policy of combined vaccination against
measles and rubella [6]. The World Health Organis-
ation, Regional Oﬃce for Europe (WHO/EURO),
established a control target of an annual incidence of
less than one case of mumps notiﬁed per 100000 of the
population to be achieved by its member countries by
2010 [7].
The European Sero-Epidemiology Network
(ESEN) was established in 1996 with the aim of
coordinating and harmonizing the serological surveil-
lance of immunity to several vaccine-preventable dis-
eases in Europe including mumps [8]. In this paper,
the standardized mumps antibody levels measured in
national serological surveys undertaken in six west
European countries are compared. This provides a
unique opportunity to compare the results of these
mumps sero-surveys, to assess the serological and
epidemiological impact of diﬀerent mumps vacci-
nation schedules, the level of vaccine coverage at-
tained and to determine progress towards mumps
control in western Europe.
METHODS
Vaccine programme structure and coverage
A questionnaire was distributed to all participating
countries to gather data on the history and the organ-
ization of the national mumps vaccine programmes,
the current and historical reported vaccine coverage,
the structure of the surveillance system for mumps dis-
ease and the age-speciﬁc incidence of notiﬁed mumps
cases. Some of these results have previously been
reported [11]. On the basis of mean reported vaccine
coverage for mumps vaccine in the 3 years prior to
the collection of the main serum banks, countries
were divided into high (vaccine coverage>90%), me-
dium (vaccine coverage 80–90%) and low coverage
countries (<80%).
Serum survey collection
Six countries in ESEN undertook testing for mumps
antibody of sera specimens collected between 1994
and 1998 (Denmark, England and Wales, France,
Germany, Italy and the Netherlands). The sera were
obtained by using the residual sera collected during
routine laboratory testing except the Netherlands,
where sera were collected by population-based ran-
dom sampling, and Denmark, where both methods
were used [9]. The number of sera collected per
country ranged from 2766 to 8303, were evenly dis-
tributed between males and females and from a var-
iety of geographical locations within each country
to provide a reasonably representative age-speciﬁc
estimate of immunity to mumps in the general
population. Further details of the sera collection have
been published elsewhere [9].
Standardization: reference panel distribution
and testing
The methodology and the results of the qualitative
and quantitative standardization of the mumps virus
antibody results has been described elsewhere [10]. In
brief, the reference centre (Robert Koch Institute,
Berlin, Germany) prepared a panel containing 150
sera that were positive, equivocal or negative as tested
using the Behring Enzygost enzyme immunoassay.
These panels were then distributed to the national
laboratory in each participant country where they
were tested with the quantitative enzyme immuno-
assay normally used tomeasure levels of serummumps
antibody.
Local titres were converted to standard titres by
regressing the results of the panel testing of the
national centre against those of the reference centre
and thus obtaining standardization equations which
could then be applied to the results of the testing of
the main serum banks. The standardization of the
assays were evaluated quantitatively by determining
the ﬁt of the equation using R2 (the square of multiple
correlation coeﬃcients) and qualitatively by assessing
the level of concordance in identifying positive,
negative and equivocal results.
Main serum bank testing
Each main national bank survey was tested using
the same validated assay method as was used for the
reference panel. The country-speciﬁc standardiz-
ation equations were then used to convert the local
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quantitative results of the serum survey into standard-
ized reference laboratory units. The reference lab-
oratory cut-oﬀs were used to re-classify qualitatively
the standardized quantitative results as negative,
equivocal or positive.
Modelled MMR vaccine coverage
A descriptive analysis was conducted in which
country-speciﬁc sero-proﬁles were interpreted in the
context of that country’s mumps vaccination pro-
gramme history (Fig. 1). MMR vaccine coverage
was estimated using modelling techniques in which
ESEN serological data at the individual level were
used to calculate the proportion of individuals of a
given age who had either been vaccinated or infected
with each of the three viruses [12]. Reported mumps
vaccine coverage was used for age groups targeted by
a mumps, but not MMR, immunization programme.
RESULTS
Mumps vaccination programmes
Routine vaccination for mumps was conducted in two
countries (West Germany and France) before the
introduction of an MMR vaccine (Table 1). In the
former West Germany a combined measles–mumps
vaccine had been available since 1976. In France,
from 1983 a single mumps vaccine was targeted at
12-month-old children until 1986 when MMR was
introduced.
By 1991, MMR had been introduced in all
countries (Table 1), all of which now have a two-
dose schedule. However, in some countries the second
dose was introduced either just prior to (France
and England and Wales in 1996) or since the com-
pletion of this study (Italy in 1999). Following the
uniﬁcation of Germany, a two-dose MMR schedule
was introduced in 1991 which replaced a one-dose
schedule that had been in place since 1981 in the for-
merWest Germany and the absence of anymumps im-
munization programme in the former East Germany.
In all countries, the ﬁrst MMR dose is targeted at
children in their second year of life (12–18 months)
but the second dose is recommended for a wide range
of ages. The majority of countries target the second
MMR dose to children aged between 3 and 6 years
old (England and Wales, France and Germany).
However, older children are targeted in Denmark (12
years old) and the Netherlands (9 years old). The Jeryl
Lynn and derived strains of mumps virus are now
used in most countries, and in Italy it replaced the
Rubini vaccine strain which was withdrawn in 2001
[13]. Vaccines using the Urabe mumps strain were
withdrawn from routine use in many countries in the
1990s due to an increased risk of vaccine-associated
mumps meningitis [14].
Reported mumps vaccine coverage
A reported coverage for the ﬁrst dose of the MMR
vaccine was available for all countries, except
Germany, and was calculated using routine data
sources except in France and Italy. In France, prior to
1993, mumps vaccine coverage at 2 years of age was
reported from routine data sources and, 1993 on-
wards, from annual surveys of 3–4 year-old children.
In Italy, regional cluster surveys using the Expanded
Programme on Immunization methodologies were
conducted in 1984, 1991 and 1998 [15, 16].
Using the reported mumps vaccine coverage in the
3 years prior to the serological surveys, England and
Wales and the Netherlands had high vaccine coverage
of greater than 90% and Denmark and France, a
medium coverage of between 80 and 90% (Table 2).
Italy and Germany were considered as countries with
low vaccine coverage. In Italy, the most recent report
of mumps vaccine coverage was less than 60%. Re-
ported MMR vaccine coverage was not available for
Germany, though modelled estimates of recent MMR
vaccine coverage was approximately 60% [12].
Mumps surveillance data
In the most recent years, the annual reported inci-
dence of mumps cases has been less than one per
100000 of the population in Denmark and in the
Netherlands (Table 1). In England and Wales, the
reported incidence of mumps in 1996 was only just
above this target (3.4/100000), although by 2000
the incidence of mumps had increased slightly to
4/100000 [17]. In Italy and France, the incidence of
reported disease was very much higher than the target
of one case per 100000 of the population. In Italy, the
incidence of mumps disease was 113/100000 in 1996.
In France, the reported annual incidence of mumps
was 84/100000, although since 1996 it has continued
to decline and in 2000 the incidence was reported as
29/100000 [18].
Mumps assay standardization
The standardization of the mumps panel was suc-
cessful with R2 values greater than 0.85. For the
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semi-quantitative comparison after standardization,
agreement was very good except for Denmark in
which 12 of the 69 positive sera identiﬁed by the
reference centre were tested negative [10].
Mumps serum bank testing and modelled MMR
vaccine coverage
In the Netherlands, despite an MMR vaccine cover-
age estimated to be consistently above 90%, the
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Fig. 1. For legend see page 697.
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sero-prevalence of mumps virus antibodies in younger
children is relatively low (Fig. 1). The sero-prevalence
was 81% in younger birth cohorts (2–8 years old)
who had received one dose MMR, lower than those
who had received a second MMR dose (9–12 years
old; 89%, x2=14.40, P<0.001). In England and
Wales, a sero-prevalence of mumps virus antibodies
greater than 80% was only found in samples collected
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from adolescents or adults (Fig. 1). Amongst young
children (2–9 years of age), the sero-prevalence is less
than 70% (Table 3), even though in these age groups
the MMR vaccine coverage has been estimated at
over 90% (Fig. 1).
In Denmark the sero-prevalence of mumps virus
antibodies greater than 80% was only found in sam-
ples collected from adolescents or adults (Fig. 1). In
children aged between 6 and 10 years old, there was a
decline with age in the sero-prevalence of mumps virus
antibodies (Fig. 1, x2test-for-trend=16.00, P<0.001),
with a low of 62% in 10-year-old children. In 13-year-
old children, the sero-prevalence was over 90%,
which coincided with an increase in the estimated
vaccine coverage as well as a second dose adminis-
tered at 12 years old. In those birth cohorts who had
received a second MMR dose (aged 12–19 years),
both the proportion of equivocal samples was lower
(Fig. 1, 4.7% vs. 14.5%, x2=22.60, P<0.001) and
the geometric mean titres were larger (714; 95%CI
655–778 vs. 2.308; 95%CI 2.107–2.52580, P<0.001)
than in those who had received only one dose of
MMR (aged 2–9 years).
In France, amongst younger children between 2
and 4 years of age, the sero-prevalence of mumps
virus antibodies was nearly 90% (Fig. 1). However,
amongst older children and adolescents (i.e. 6–15
years of age), the sero-prevalence of mumps virus
antibodies declined to less than 80%, which corre-
sponded with a decline in the estimated vaccine cover-
age. In Italy, the modelled vaccine coverage of the
one dose MMR vaccine programme exceeded 50%
only in recent years, an increase from the initial cover-
age of 25% (Fig. 1). Of all the six countries, the lowest
sero-prevalence amongst children was observed in
Italy and a sero-prevalence of mumps virus antibodies
greater than 80% was observed only amongst those
older than 14 years of age (Table 3, Fig. 1).
The sero-proﬁles of the former German states are
presented separately (Table 3, Fig. 1) as only in the
former West Germany was a mumps vaccination
programme in place until reunion in 1991, even
though vaccine coverage was estimated to be low
(approximately 30%). The sero-proﬁles of the former
East and West Germany were similar, the proportion
of sero-negative samples declined with age, from
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Fig. 1. Seroprevalence of mumps virus antibody for each country (dark bars, mumps virus antibody positive ; light bars
equivocal). The vaccine coverage in each age group is either estimated from modelling studies (when immunization is
with MMR vaccine) or reported data when mumps vaccine is used alone (France in 15–18 year olds) or in combination
with a measles vaccine (West Germany in 16–34 year olds). Vaccine history was deﬁned as MMR1 (single dose MMR
mass vaccination programme) ; MMR2 (second dose MMR mass vaccination programme) ; catch-up MMR: mumps or
measles–mumps.
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approximately a third of children aged 2–4 year olds
to less than 10% amongst adults. Only amongst 15–
19 year olds was a diﬀerence in the sero-proﬁles noted
(Table 3) with the proportion of mumps virus anti-
body negative samples greater amongst those in the
former West Germany than in the former East (16%
vs. 6%, x2=17.79, P<0.001).
DISCUSSION
This report describes the comparative sero-epidemi-
ology of mumps infection in six European countries.
The aim of the ESEN project was to standardize
serum bank testing so that by establishing a common
standardized unitage for assay titres, international
comparison could be made. In this study, all partici-
pant countries used the presence of mumps virus
serum IgG antibodies, as measured by enzyme
immuno-assays, as a marker of immunity.
In the pre-vaccination age groups, mumps was a
childhood illness and most individuals had acquired
immunity by early adulthood [19]. The MMR vaccine
programmes, introduced in most west European
countries during the 1980s, have targeted children. In
Table 1. Immunization strategies for mumps in six European countries at the time of the ESEN study, 1998
Denmark France Italy
England and
Wales Germany Netherlands
Strategy prior to MMR
introduction
None Yes* None None Yes# None
Year of MMR
introduction
1987 1986 1982 1988 1991 1987
Recommended number
of doses of MMR
2 2$ 1· 2k 2 2
Age groups targeted 15 months 12 months 12–15 months 12–18 months 12–15 months 14 months
12 years 3–6 years 4 years 6 years 9 years
Mumps strains used in
MMR
Jeryl Lynn Jeryl Lynn Rubini"
Urabe
Jeryl Lynn** Jeryl Lynn Jeryl Lynn
* A one-dose mumps vaccine at 12 months introduced in 1983.
# In the former West Germany, a measles–mumps vaccine was introduced in 1976 and replaced by a single MMR dose at
15 months in 1981.
$ In 1996 introduction of second MMR dose targeted at 11–13 year olds and then 3–6 year olds in 1997.
· A second MMR dose introduced in 1999 for children aged 6–12 years of age.
k Single dose MMR until 1996.
" Rubini strain vaccines replaced by Jeryl Lynn strains in July 2001.
** Urabe strain vaccines withdrawn in 1992.
Table 2. Incidence of reported mumps disease (/100000) and reported coverage of MMR vaccine by 2 years
of age in ﬁve European countries, from 1990 to the end of the ESEN study in 1998
Year
Denmark England and Wales France Italy Netherlands
Incidence
(/100000)
Vaccine
coverage
Incidence
(/100000)
Vaccine
coverage
Incidence
(/100000)
Vaccine
coverage*
Incidence
(/100000)
Vaccine
coverage
Incidence
(/100000)
Vaccine
coverage
1990 8.8 84 26.0 86 187.9 54 106.3 0.2 95
1991 6.1 86 20.8 90 221.5 52 71.4 9–53# 0.3 94
1992 3.6 85 15.6 92 242.9 62 51.1 0.3 94
1993 2.9 81 4.2 91 159.9 80 51.0 0.3 95
1994 0.5 88 4.8 91 93.1 84 66.3 0.2 94
1995 0.2 88 3.7 92 84.1 85 115.1 0.2 94
1996 0.8 85 3.4 92 83.8 88 112.9 0.2 94
1997 0.6 84 3.7 91 70.0 89 51.6 0.3 96
1998 0.4 88 3.0 88 45.0 91 25.6 26–87# 0.2 96
* Up to 1992, vaccine coverage was reported for 2-year-old children, and from 1993 for 3–4-year-old children.
# Vaccine coverage estimated using cluster sampling of 2-year-old children.
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some countries, notably Denmark, England and
Wales and the Netherlands, the sero-prevalence of
antibodies to mumps virus in these age groups was
much lower than either reported or estimated vaccine
coverage. The discordance between vaccine coverage
and immunity in the population may be due to the
assay employed, including problems in the standard-
ization procedure, or due to primary or secondary
vaccine failure.
The standardization of assay results permitted the
comparison of immunity to mumps in several diﬀer-
ent European countries, although there remained
variations in laboratory cut-oﬀs and some residual
lack of comparability [10]. For example, despite the
standardization of the Danish assay results, a lower
sero-positivity was observed [10], which may explain,
in part, the discordance between sero-prevalence and
vaccine coverage data. The EIA are more sensitive
than other techniques [20, 21], probably due to the
detection of antibodies involved in complement-
mediated immunity [20, 21]. Diﬀerent EIAs were used
in the Netherlands and England and Wales to that of
the reference centre, and as mumps antibody titre can
vary with the virus antigen used in the assay [22], this
may also explain the observed discordance in sero-
prevalence and vaccine coverage [10]. The develop-
ment of an international mumps reference antibody
preparation will further enhance the comparability of
mumps sero-prevalence data [10, 23].
Failure of the mumps vaccine has been attributed
to primary vaccine failure [24]. Sero-conversion rates
following mumps vaccination, estimated by modelling
ESEN sero-prevalence data, varied in the diﬀerent
countries [12]. For example, in the Netherlands, the
sero-conversion rate was estimated to be 82% [12]
and this may explain some of the observed discor-
dance in vaccine coverage and sero-prevalence. In
Italy, where until recently the Rubini strain was
commonly used, modelled sero-conversion rates were
very low – approximately 60% [12]. The Rubini
strain has been shown not to oﬀer good protection
against the disease [25, 26], and the use of this strain in
the MMR vaccine, as well as the poor vaccine cover-
age, may have contributed to the low mumps virus
antibody positivity observed.
The administration of a second MMR dose has
been shown to boost serum IgG antibody levels [27,
28], although it remains unclear whether waning anti-
body levels represents secondary vaccine failure or
if other mechanisms of immunity exist [24, 28]. In
Denmark and in the Netherlands, an increase
in mumps virus antibody positivity was observed in
those birth cohorts in whom a second MMR dose
had been administered. However, no consistent trend
was observed, although, at the time of the study, three
of the six countries had only just implemented a two-
dose MMR immunization strategy. In countries
with well-established vaccine programmes, the lack
of circulating wild virus may not boost immune re-
sponses, resulting in waning immunity. In contrast,
there would be circulation of wild virus in countries
with poor vaccine programmes. This may partly ex-
plain the discrepancy between vaccine coverage and
mumps virus antibody prevalence noted in Denmark,
Netherlands, England and Wales, but not in Italy and
Germany.
The level of population immunity required to block
transmission of mumps has been estimated using
mathematical models to be between 85 and 90% [19,
29, 30]. In countries with high vaccine coverage, such
Table 3. Percentage mumps virus antibody negative by age group for countries participating in ESEN, 1994–98.
(n is the number of samples tested ).
Percentage mumps virus antibody negative by age group
12–23 months 2–4 years 5–9 years 10–14 years 15–19 years 20+ years
Country % (n) % (n) % (n) % (n) % (n) % (n)
Denmark 53.1 (96) 32.3 (269) 19.3 (458) 15.5 (497) 6.8 (340) 5.8 (1409)
England and Wales 42.0 (100) 32.1 (299) 31.2 (500) 23.6 (499) 9.0 (500) 9.4 (1400)
France 38.5 (65) 12.9 (194) 18.0 (294) 19.0 (274) 10.2 (364) 3.3 (1644)
East Germany 88.4 (153) 31.8 (327) 19.1 (634) 13.3 (445) 5.8 (295) 5.6 (144)
West Germany 80.4 (56) 36.6 (227) 20.8 (419) 16.4 (397) 16.1 (429) 6.9 (1373)
Italy 79.8 (100) 52.5 (339) 33.2 (542) 21.3 (520) 12.7 (671) 6.3 (1455)
Netherlands 50.8 (250) 18.0 (573) 18.6 (559) 13.3 (580) 8.8 (455) 7.5 (5261)
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as the Netherlands, the proportion of older children
and adolescents with antibodies to mumps virus was
above these levels. In contrast, in countries with poor
vaccine coverage, such as Italy, large proportions of
susceptibles were noted in these older age groups,
although almost all individuals had become immune
by early adulthood due to the continued circulation
of the wild virus. We noted large proportions of sus-
ceptibles amongst older children and adolescents
in England and Wales, France, the former West
Germany and Italy, and it is in older age groups that
the sequelae of mumps are more serious [31]. Recent
outbreaks of mumps in secondary educational estab-
lishments [32, 33] demonstrate the continuing possi-
bility of outbreaks in these older age groups [30].
Denmark and the Netherlands have achieved the
WHO/EURO target of less than one case of mumps
annually per 100000 of the population. England and
Wales are close to achieving this target, although this
is not the case in France or Italy. These discrepancies
in incidence of disease between countries with similar
vaccine coverage may be due to diﬀerent histories of
immunization programmes. However, the use of sur-
veillance data for either setting targets or to compare
disease epidemiology between diﬀerent countries is
fraught with diﬃculties [11]. For example, in France,
unlike other countries, the mumps incidence data is
extrapolated to account for the incompleteness of
mumps notiﬁcations [34]. Although laboratory con-
ﬁrmation of mumps cases has been recommended,
especially in countries with a low incidence, to mini-
mize the poor sensitivity of clinical case deﬁnitions [5],
only in England and Wales is this practiced using
salivary samples [30].
To control mumps in the countries involved in this
study, MMR immunization programmes will need to
be either strengthened or maintained by ensuring that
a two-dose immunization schedule is employed and
that vaccine coverage of the ﬁrst dose is greater than
90%. Alongside the enhancement of the MMR vac-
cine programmes, measures to improve the surveil-
lance of both the mumps immunization programme
and disease, such as routine vaccine coverage, age-
and sex-speciﬁc incidence data including the labora-
tory conﬁrmation of cases, will need to be introduced
in many countries. Sero-surveillance of mumps is an
important component in the monitoring of disease
elimination targets as, unlike reported surveillance of
disease, a clearer picture of population susceptibility
is obtained and these data are less open to biases.
In future, the sero-surveillance of mumps will be
enhanced by the development of an international
standard [23].
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